Valion Bio (VBIO) EBITDA Margin Growth (1y) (2022 - 2026)
Valion Bio (VBIO) EBITDA Margin Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | -1,651.00 |
| 10 | Valion Bio | 404,923.65 | -1.80 Mn | -45,000.00 | 213,345.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213,345.00 |
| Dec 31, 2025 | 91,514.00 |
| Sep 30, 2025 | -56,497.00 |
| Jun 30, 2025 | -134,455.00 |
| Mar 31, 2025 | -170,802.00 |
| Dec 31, 2024 | -19,532.00 |
| Sep 30, 2024 | -51,160.00 |
| Jun 30, 2024 | 41,559.00 |
| Mar 31, 2024 | 11,935.00 |
| Dec 31, 2023 | -7,563.00 |
| Sep 30, 2023 | -8,239.00 |
| Jun 30, 2023 | -74,828.00 |
| Mar 31, 2023 | -3,917.00 |
| Dec 31, 2022 | 3,626.00 |
| Sep 30, 2022 | -9,804.00 |
| Jun 30, 2022 | -17,793.00 |
| Mar 31, 2022 | -19,635.00 |